0001628280-22-000336.txt : 20220105 0001628280-22-000336.hdr.sgml : 20220105 20220105165948 ACCESSION NUMBER: 0001628280-22-000336 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220103 FILED AS OF DATE: 20220105 DATE AS OF CHANGE: 20220105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aurentz Vincent CENTRAL INDEX KEY: 0001657494 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 22512016 BUSINESS ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 453-7200 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: Vincent Aurentz DATE OF NAME CHANGE: 20151103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 wf-form4_164141997456000.xml FORM 4 X0306 4 2022-01-03 0 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001657494 Aurentz Vincent C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 0 1 0 0 Executive VP and CBO Common Stock 2022-01-03 4 A 0 21462 0 A 55122 D The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on February 15, 2023, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of May, August, November, and February. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units. /s/ Andrew J. Cronauer, as Attorney-in-Fact 2022-01-05